An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
NCT00686088
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Locally Recurrent Prostate Cancer
Interventions
DRUG:
PRX302
Sponsor
Sophiris Bio Corp